Helus Pharma, Inc. (HELP)
6.11
-0.67
(-9.88%)
USD |
NASDAQ |
Nov 20, 16:00
6.18
+0.07
(+1.15%)
After-Hours: 20:00
Helus Pharma Enterprise Value : 315.95M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 315.95M |
| November 19, 2026 | 369.25M |
| November 18, 2026 | 378.00M |
| November 17, 2026 | 402.66M |
| November 16, 2026 | 440.05M |
| November 13, 2026 | 535.51M |
| November 12, 2026 | 534.71M |
| November 11, 2026 | 576.87M |
| November 10, 2026 | 551.42M |
| November 09, 2026 | 575.28M |
| November 06, 2026 | 542.67M |
| November 05, 2026 | 497.32M |
| November 04, 2026 | 520.39M |
| November 03, 2026 | 548.24M |
| November 02, 2026 | 529.94M |
| October 30, 2026 | 672.73M |
| October 29, 2026 | 681.88M |
| October 28, 2026 | 697.79M |
| October 27, 2026 | 666.77M |
| October 26, 2026 | 654.04M |
| October 23, 2026 | 640.51M |
| October 22, 2026 | 665.18M |
| October 21, 2026 | 687.45M |
| October 20, 2026 | 700.18M |
| October 19, 2026 | 680.29M |
| Date | Value |
|---|---|
| October 16, 2026 | 669.15M |
| October 15, 2026 | 708.93M |
| October 14, 2026 | 655.63M |
| October 13, 2026 | 665.18M |
| October 12, 2026 | 707.34M |
| October 09, 2026 | 768.59M |
| October 08, 2026 | 682.68M |
| October 07, 2026 | 665.97M |
| October 06, 2026 | 685.86M |
| October 05, 2026 | 738.36M |
| October 02, 2026 | 760.64M |
| October 01, 2026 | 777.34M |
| September 30, 2026 | 807.57M |
| September 29, 2026 | 620.83M |
| September 28, 2026 | 614.01M |
| September 25, 2026 | 615.25M |
| September 24, 2026 | 614.01M |
| September 23, 2026 | 640.67M |
| September 22, 2026 | 683.44M |
| September 21, 2026 | 680.34M |
| September 18, 2026 | 600.38M |
| September 17, 2026 | 702.65M |
| September 16, 2026 | 668.56M |
| September 15, 2026 | 646.87M |
| September 14, 2026 | 677.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NervGen Pharma Corp. | 142.12M |
| Milestone Pharmaceuticals, Inc. | 44.61M |
| Appili Therapeutics, Inc. | 9.454M |
| Clearmind Medicine, Inc. | -13.43M |
| GH Research Plc | 853.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -103.09M |
| Total Expenses (Quarterly) | 103.09M |
| EPS Diluted (Quarterly) | -1.411 |
| Earnings Yield | -69.77% |
| Normalized Earnings Yield | -69.67 |